GSK One Step Closer To Its DREAM: Washout Data From Diabetes Prevention Trial Due In December
This article was originally published in The Pink Sheet Daily
Executive Summary
Increase in fat distribution at hip may be tied to Avandia’s diabetes prevention mechanism.
You may also be interested in...
GSK Adopting New Marketing Push For Avandia
ADOPT trial results, which show rosiglitazone beats metformin for maintaining glycemic control, could double the market for the insulin sensitizer.
GSK Adopting New Marketing Push For Avandia
ADOPT trial results, which show rosiglitazone beats metformin for maintaining glycemic control, could double the market for the insulin sensitizer.
Diabetes Prevention Drugs Will Be Addressed In FDA Guidance
Metabolic syndrome may also be discussed in draft document expected to be out by year-end.